HilleVax (HLVX) Competitors $2.09 0.00 (0.00%) As of 09/17/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HLVX vs. UPXI, EOLS, AMRN, AUTL, FDMT, YMAB, LRMR, DBVT, ETHZ, and KMDAShould you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include Upexi (UPXI), Evolus (EOLS), Amarin (AMRN), Autolus Therapeutics (AUTL), 4D Molecular Therapeutics (FDMT), Y-mAbs Therapeutics (YMAB), Larimar Therapeutics (LRMR), DBV Technologies (DBVT), Flag Ship Acquisition (ETHZ), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. HilleVax vs. Its Competitors Upexi Evolus Amarin Autolus Therapeutics 4D Molecular Therapeutics Y-mAbs Therapeutics Larimar Therapeutics DBV Technologies Flag Ship Acquisition Kamada HilleVax (NASDAQ:HLVX) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Do insiders & institutionals hold more shares of HLVX or UPXI? 86.4% of HilleVax shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 24.9% of HilleVax shares are held by company insiders. Comparatively, 4.4% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher valuation & earnings, HLVX or UPXI? Upexi has higher revenue and earnings than HilleVax. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHilleVaxN/AN/A-$147.27M-$1.43-1.46Upexi$15.81M26.70-$13.68MN/AN/A Does the media refer more to HLVX or UPXI? In the previous week, Upexi had 3 more articles in the media than HilleVax. MarketBeat recorded 3 mentions for Upexi and 0 mentions for HilleVax. Upexi's average media sentiment score of 1.31 beat HilleVax's score of 0.00 indicating that Upexi is being referred to more favorably in the news media. Company Overall Sentiment HilleVax Neutral Upexi Positive Is HLVX or UPXI more profitable? HilleVax has a net margin of 0.00% compared to Upexi's net margin of -86.54%. HilleVax's return on equity of -34.29% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets HilleVaxN/A -34.29% -28.50% Upexi -86.54%-54.33%-31.28% Do analysts recommend HLVX or UPXI? HilleVax presently has a consensus price target of $2.00, suggesting a potential downside of 4.31%. Upexi has a consensus price target of $15.50, suggesting a potential upside of 116.18%. Given Upexi's stronger consensus rating and higher possible upside, analysts plainly believe Upexi is more favorable than HilleVax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HilleVax 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Upexi 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has more risk & volatility, HLVX or UPXI? HilleVax has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Upexi has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. SummaryUpexi beats HilleVax on 8 of the 14 factors compared between the two stocks. Get HilleVax News Delivered to You Automatically Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HLVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HLVX vs. The Competition Export to ExcelMetricHilleVaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$104.79M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-1.4621.5785.3527.60Price / SalesN/A271.49539.78202.41Price / CashN/A47.1237.9261.55Price / Book0.6710.1413.016.76Net Income-$147.27M-$52.31M$3.30B$275.88M7 Day PerformanceN/A5.14%4.34%2.81%1 Month Performance-0.48%14.68%9.49%9.24%1 Year Performance20.81%30.98%84.83%35.42% HilleVax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HLVXHilleVax1.0771 of 5 stars$2.09flat$2.00-4.3%N/A$104.79MN/A-1.4620UPXIUpexi2.7425 of 5 stars$7.05-8.4%$15.50+119.9%+173.7%$415.17M$15.81M0.00130Positive NewsEOLSEvolus3.9743 of 5 stars$6.26-2.6%$21.25+239.5%-62.4%$404.93M$277.94M-6.39170AMRNAmarin0.4984 of 5 stars$19.27-0.3%$12.00-37.7%+62.0%$398.56M$219.36M-5.25360News CoverageAnalyst ForecastHigh Trading VolumeAUTLAutolus Therapeutics3.5361 of 5 stars$1.49-4.5%$9.12+512.1%-56.7%$396.55M$29.93M-1.77330Positive NewsAnalyst ForecastFDMT4D Molecular Therapeutics2.4364 of 5 stars$8.32-1.0%$30.40+265.4%+3.0%$392.30M$33K-2.36120Positive NewsAnalyst ForecastYMABY-mAbs Therapeutics1.7173 of 5 stars$8.61flat$9.62+11.8%N/A$391.24M$87.68M-17.22150LRMRLarimar Therapeutics2.7932 of 5 stars$4.72-1.9%$16.71+254.1%-32.0%$390.71MN/A-3.0330Analyst ForecastHigh Trading VolumeDBVTDBV Technologies1.5625 of 5 stars$14.24+7.1%$14.75+3.6%+344.0%$390.11MN/A-2.9980Analyst ForecastGap UpETHZFlag Ship AcquisitionN/A$2.33-8.6%N/AN/A$383.12MN/A-0.157News CoverageAnalyst ForecastHigh Trading VolumeKMDAKamada4.5351 of 5 stars$6.65-0.7%$13.00+95.5%+30.0%$382.44M$160.95M19.56360Positive NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies UPXI Competitors EOLS Competitors AMRN Competitors AUTL Competitors FDMT Competitors YMAB Competitors LRMR Competitors DBVT Competitors ETHZ Competitors KMDA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HLVX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HilleVax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
